Bile alcohol metabolism in man. Conversion of 5beta-cholestane-3alpha, 7alpha,12alpha, 25-tetrol to cholic acid. To study the role of C25-HYDROXY BILE ALCOHOLS AS PRECURSORS OF CHOlic acid, [G-3-H]5beta-cholestane-3alpha,7alpha12alpha,25-tetrol was administered intravenously to two subjects with cerebrotendinous xanthomatosis (CTX) and two normal individuals. One day after pulse labeling, radioactivity was present in the cholic acid isolated from the bile and feces of the subjects with CTX and the bile of the normal individuals. In the two normal subjects, the sp act decay curves of [G-3-H]-cholic acid were exponential, and no traces of [G-3-H]-5beta-cholestane-3alpha,7alpha,12alpha,25-tetrol were detected. In contrast, appreciable quantities of labeled 5beta-cholestane-3alpha,-7aopha,12alpha,25-tetrol were present in the bile and feces of the CTX subjects. The sp act vs. time curves of fecal [G-3-H]5beta-cholestane-3alpha,7alpha,12alpha,25-tetrol and [G-3-H]-cholic acid showed a precursor-product relationship. Although these results suggest that 5beta-cholestane-3alpha,7alpha,12alpha,25-tetrol may be a precursor of cholic acid in man, the possibility that C26-hydroxy intermediates represent the normal pathway can not be excluded.
INTRODUCTION
In the rare inherited sterol storage disease, cerebrotendinous xanthomatosis (CTX),' bile acid production is subnormal (1) but considerable quantities of CG bile alcohols are excreted in bile and feces (2) . Two bile alcohols have been identified conclusively: 5/8-cholestane-3a,7a, 12a,25-tetrol and 5p-cholestane-3a,7a,12a,24t,-25-pentol (2) , and thus it appears that diminished bile acid synthesis in CTX results from defective oxidation Received of the cholesterol side chain. However, according to current views on bile acid biosynthesis, bile alcohols hydroxylated at carbon 25 are not considered precursors of bile acids (3) . Fig. 1 illustrates two possible pathways for cholic acid 2 synthesis from cholesterol. The steroid nucleus undergoes change first and the key rate-determining reaction is the transformation of cholesterol (1) to 7a-hydroxycholesterol (II) followed by oxidation of the hydroxyl group on carbon 3 to a ketone and migration of the double bond to the 4,5 position to form 7a-hydroxycholest-4-en-3-one (III) . At this point, 7a-hydroxycholest-4-en-3-one (III) is 12a-hydroxylated to yield 7a,12a-dihydroxycholest-4-en-3-one (IV) , and this compound is reduced to 5fl-cholestane-3a,7a,12a-triol (V). Side chain degradation now proceeds, and according to Staple (4) , 5P-cholestane-3a,7a,12a-triol is hydroxylated at carbon 26 to form 5P-cholestane-3a,-7a,12a,26-tetrol (VI), which is oxidized to 3a,7a,12a-trihydroxy-5P-cholestanoic acid and then hydroxylated at carbon 24, forming 3a,7a,12a,24E-tetrahydroxy-5,8-cholestanoic acid (VII). f-Oxidation of the Coenzyme A derivative of this compound gives cholic acid (X) and propionic acid. However, the accumulation of considerable quantities of the two bile alcohols hydroxylated at carbon 25 in CTX suggested that cholic acid may be produced from 5P-cholestane-3a,7a,12a,25-tetrol and 5.8-cholestane-3a,7a,12a,24t,25-pentol. In this study, the formation of bile acid from radioactive 5P-cholestane3a,7a,12a,25-tetrol was examined in normal and CTX 7a-hydroxycholest-4-en-3-one; IV, 7a,12a-dihydroxycholest-4-en-3-one; V, 5#-cholestane-3a,7a,12a-triol; VI, 5fi-cholestane-3a,7a,12a,26-tetrol; VII, 3a,7a,12a,244-tetrahydroxy-5,B-cholestanoic acid; VIII, 5j-cholestane-3a,7a,12a,25-tetrol; IX, 5,8-cholestane-3a, 7a,12a,24t,25-pentol; and X, cholic acid. 12a,25-tetrol was indeed converted into cholic acid in man.
METHODS
Clinical. Studies were conducted in two subjects with CTX (E. E. and E. S.) and two normolipidemic individuals (J. S. and A. S.). Complete clinical descriptions and metabolic data of the CTX subjects have been published (1, 5) . The patients were hospitalized at the East Orange Veterans Administration Hospital and were fed regular hospital diets during the course of this investigation.
Steroid analyses. Stool specimens were collected from both CTX subjects and were combined into 2-day pools. Extraction of bile alcohols and bile acids from bile and feces. A weighed specimen of dried bile or feces was extracted with a mixture of 300 ml of ethanol and 2 ml of concentrated NHtOH in a Soxhlet apparatus. The ethanol extract was evaporated on a 60'C water bath under nitrogen leaving a residue that was suspended in 200 ml of water containing 1 ml of concentrated NH40H.
The neutral lipids (cholesterol, cholestanol, sterol precursors, and bile alcohols) were extracted from the aqueous suspension containing the conjugated bile acids with three 100-ml portions of ethyl acetate. The ethyl acetate extracts were combined, washed, and the solvent removed in a rotary evaporator. The neutral lipids were dissolved in 5 ml of ethyl acetate.
To isolate the bile acids, the remaining aqueous phase was concentrated to about 100 ml by evaporation under nitrogen. About 8 g of NaOH was added to make the solution 2 N, and the mixture was heated at 1200C in an autoclave for 3 h. The mixture was cooled in ice and acidified to pH 2 by the addition of concentrated HCL. 200 ml of peroxide-free ethyl ether was added, and the free bile acids were extracted into the ether phase; two additional extractions with 100-ml portions of ether were performed. The ether phases were pooled, washed with water, and evaporated in a rotatory evaporator.
Isolation of 5,8-cholestane-3a,7a,12a,25-tetrol. The ethyl acetate extract was applied to an alumina column (neutral alumina, grade V, 100-200 mesh, Calbiochem, San Diego, Calif.). Neutral sterols (cholesterol, cholestanol, and plant sterols) were eluted with 100 ml ethyl acetate. 5j3-cholestane-3a,7a,12a,25-tetrol was eluted with 100 ml 5% methanol in ethyl acetate, and the pentahydroxy bile alcohols were eluted with 100 ml of 10% methanol in ethyl acetate. The fraction eluted with 5%o methanol in ethyl acetate was ob- eluted with methanol after visualization with I2 vapor. The solvent was evaporated and the residue was dissolved in exactly 5 ml of methanol containing 100 ,Ag of 5a-cholestane as an internal standard. 4 ml was taken for radioactivity assay and the remainder for gas-liquid chromatography (GLC)Q.
GLC. 5,-cholestane-3a,7a,12cs,25-tetrol and methyl cholate were quantitated as trimethylsilyl derivatives using Sacholestane as an internal standard and authentic 5j3-cholestane-3a,7a,12a,25-tetrol and methyl cholate as external standards. Aliquots containing 2-10 ,ug of 5,B-cholestane-3a, 7a,12a,25-tetrol or methyl cholate were injected into 6-ft glass columns packed with 3% QF-1 on Gas Chrom Q (100-120 mesh, Applied Science Labs, Inc., State College, Pa.). The instrument was a Hewlett-Packard Model 7610A (Hewlett-Packard Co., Palo Alto, Calif.) equipped with a flame ionization detector and electronic integrator. The following operating conditions were employed: column temperature, 230°C; detector, 2500C; and flash heater, 250°C.
Radioactivity measurements. Radioactivity was measured in a Beckman Model LS-200 B liquid scintillation spectrometer (Beckman Instruments, Inc., Fullerton, Calif.). Appropriate corrections were made for quench and background. The counting efficiency for tritium was 51%o.
Preparation of [G-'H]5,f-cholestane-3ac,7a,12a,25-tetrol. 5p-cholestane-3a,7a,12a,25-tetrol (6) was tritium labeled by the Wilzbach technique at New England Nuclear, Boston, Mass. (7). The radioactive material (5 mg) was diluted with pure, unlabeled tetrol (5 mg) and purified by chromatography on alumina and then recrystallized from ethyl acetate to constant specific radioactivity. The radiopurity of this material was monitored by repeated TLC and found to be 98% cholestanetetrol. The purified labeled tetrol (20 ttCi/mg) was dissolved in ethanol to give a solution containing 2 ,Ci/ml. Each patient received 2 ,uCi of labeled tetrol dispersed in 150 ml of 0.9%o NaCl solution by intravenous njection.
RESULTS
Conversion of 5,3-cholestane-3a,7a,12a,25-tetrol into cholic acid Normal man. About 2 uCi of [G-3H]59-cholestane3a,7a,12a,25-tetrol was injected intravenously into two normolipidemic men, and samples of intestinal bile were obtained over the next 9 days. Cholic acid was isolated and purified from each bile specimen. The results are presented in Table I and Fig. 2 . In both individuals, the cholic acid was labeled with tritium which indicated that [G-'H]5P-cholestane-3a,7a,12a,25-tetrol had been converted to the bile acid. The highest sp act was found 1 day after intravenous pulse labeling showing that the bile alcohol was transformed rapidly into cholic acid. The subsequent exponential decay curve ruled out continuous formation of cholic acid from a slowly turning over pool of bile alcohol, a finding supported by the absence of mass or radioactivity corresponding to 5P-cholestane-3a,7a, 12a,25-tetrol in the bile. As expected, no radioactivity was detected in chenodeoxycholic acid isolated from these subjects.
CTX t Crystallized material had same sp act as the material eluted from the thin-layer plate.
thermore, analysis of the sp act time curves shows that the cholic acid curve intersects with the cholestanetetrol curve at its maximum sp act and suggests a precursorproduct relationship (8) . This finding implies that a large portion of the cholic acid was formed from 5X-cholestane-3a,7a,12a,25-tetrol in these patients.
DISCUSSION
The results of this investigation clearly demonstrate that cholic acid was formed from 513-cholestane-3a,7a,-12a,25-tetrol in both normal and CTX individuals. In the former group, the maximum radioactivity was detected in the cholic acid 1 day after labeling with [G-3H] 59-cholestane-3a,7a,12a,25-tetrol. This observation indicated that the side chain of the labeled Cmshydroxy tetrol was oxidized to a carboxylic acid. In the CTX subjects not only was radioactivity from [G-3H]-59-cholestane-3a,7a,12a,25-tetrol detected in cholic acid isolated from bile and feces, but the sp act vs. time curves of fecal 59-cholestane-3a,7a, 12a,25-tetrol and cholic acid suggested a precursor-product relationship. The theoretical considerations underlying this relationship have been published in a recent review by Reiner (8) . As we have previously noted, the precursor-product relationship indicates that 5fi-cholestane-3a,7a,12a,-25 tetrol was a major precursor of cholic acid in these subjects.
These findings have at least two important implications. First, as concerns CTX, they support our hypothesis that the genetic abnormality in this disease results in impaired bile acid synthesis, specifically, incomplete degradation of the cholesterol side chain. The demonstration of delayed conversion of 5,B-cholestane3a,7a,12a,25-tetrol into cholic acid as compared with normolipidemic subjects coupled with the persistance of 51-cholestane-3a,7a,12a,25-tetrol and 5P-cholestane3a,7a,12a,24t,25-pentol in bile and feces suggests that the cholic acid synthetic pathway is blocked distal to the formation of these bile alcohols. Presumably, there is a diminished capacity of an enzyme that catalyzes the oxidation of either the tetrol or pentol (2) . However, an alternative explanation that might account for the accumulation of these bile alcohols is that 26-hydroxylation of 5P6-cholestane-3a,7a,12a-triol is subnormal. Although this study clearly shows that cholic acid is produced from 513-cholestane-3a,7a,12a,25-tetrol, the normal pathway might still involve 50-cholestane-3a,7a,12a,26-tetrol which is formed from the 26-hydroxylation of 51-cholestane-3a,7a,12a-triol by hepatic mitochondria (9) . Thus the accumulation of Css-hydroxy bile alcohols in CTX might represent side products rather than normal cholic acid intermediates. However, an observation in favor of Cms-hydroxy bile alcohols as intermediates of cholic acid in man is the recent demonstration by Bjorkhem, Gustafsson, Johansson and Persson (9) that 59-cholestane-3a,7a,12a,25-tetrol was preferentially formed from 5P-cholestane-3a,7a,12a-triol by human hepatic microsomes. Only trace amounts of the Cmhydroxy derivative 59-cholestane-3a,7a,12a,26-tetrol or other cholestanetetrols were formed. In contrast, these investigators showed that human liver mitochondria could 26-hydroxylate a variety of bile alcohols including 230 G. Salen, S. Shefer, T. Setoguchi, and E. H. Mosbach 5fi-cholestane-3a,7a,12a-triol. Furthermore, the microsomal system acting on 5p-cholestanetriol was much more active in producing 59-cholestane-3a,7a,12a,25-tetrol. Consequently, the production of Crs-hydroxy bile alcohols by human liver microsomes appears to be considerably more specific than the comparable system in the rat where incubation of 5P-cholestane-3a,7a,12a-triol gives a mixture of 5P-cholestanetetrols. However, even in the rat, the formation of 5P-cholestane-3a,7a,-12a,25-tetrol predominates (10) .
It is important to explain the differences in the experiments between the normal and CTX subjects. In the normal subjects, cholic acid was isolated from bile rather than feces to provide as much cholic acid as possible for characterization and radioactivity assay. It is often noted that only small amounts of cholic acid remain in the feces because of bacterial transformation to deoxycholic acid during intestinal transit. In the CTX subjects, kinetic observations were made on 5p-cholestane-3a,7a,12a,25-tetrol and cholic acid isolated from the feces because: (a) very little bacterial transformations of fecal steroids are seen in these subjects (5); and (b) large amounts of both cholic acid and 5P-cholestane-3a,7a,12a,25-tetrol can be recovered from feces without sampling the enterohepatic circulation (2). However, as noted, the sp act of biliary cholic acid was sixfold lower in the CTX subjects 1 day after pulse labeling than in the control individuals even though each subject received the same dose of [G-'H]5g-cholestane-3a,7a, 12a,25-tetrol. This observation suggests that cholic acid synthesis was reduced in the CTX subjects and is consistent with earlier quantitative measurements showing low bile acid production (1).
The second important point derived from this study concerns the pathway of cholic acid biosynthesis. It is well established that cholic acid is formed from 5P-cholestane-3a,7a,12a-triol, and oxidation of the side chain was believed to proceed exclusively via 5P-cholestane3a,7a,12a,26-tetrol and 3a,7a,12a-trihydroxy-5P-cholestanoic acid (3, 4, (11) (12) (13) . Furthermore, the conversion of 5P-cholestane-3a,7a,12a-triol to 5P-cholestane-3a,7a,12a,-26-tetrol has been shown to be catalyzed by mitochondrial enzymes (9) . On the basis of the present findings, it seems that side chain cleavage can proceed also via 5P-cholestane-3a,7a,12a,25-tetrol and probably 5P-cholestane-3a,7a,12a,244,25-pentol. Moreover, as shown by Bjorkhem et al. (9) , this transformation is catalyzed specifically by microsomal rather than mitochondrial enzymes. If cholic acid biosynthesis involves C25-hydroxy intermediates, then it is not necessary to postulate the transport of 5P-cholestane-3a,7a, 12a-triol from microsomes to mitochondria. It is important to emphasize that these remarks are confined solely to the degradation of the side chain during cholic acid biosynthesis. At the present time, there is no information that cleavage of the side chain as part of chenodeoxycholic acid synthesis proceeds via the same pathway. If so, the steps would involve the 25-hydroxylation of 5P-cholestane-3a,-7a-diol to yield 5P-cholestane-3a,7a,25-triol. However, the studies of Bjdrkhem et al. (9) showed that 5f-cholestane-3a,7a-diol was considerably less 25-hydroxylated by human liver microsomes than 5#-cholestane-3a,7a,-12a-triol. Therefore, there is the possibility that different pathways exist for the oxidation of the side chain for cholic acid and chenodeoxycholic acid synthesis.
